Clinical Trials Logo

Schizophrenia clinical trials

View clinical trials related to Schizophrenia.

Filter by:

NCT ID: NCT03775564 Active, not recruiting - Schizophrenia Clinical Trials

Effectiveness of the RemedRugby Program

RemedRugby
Start date: November 2014
Phase: N/A
Study type: Interventional

REMEDRUGBY's objective is to strengthen the capacity of users to interact with others in an assertive way and to fight against stigma. It proposes to specifically target the processes of "social cognition". "Social cognition" brings together the mental mechanisms that allow everyone to decipher the social situations, emotions and intentions of others and interact with others in the different contexts of everyday life. People with a psychic handicap frequently have difficulties in this area, which has often important consequences for their social and professional integration. The REMEDRUGBY program proposes to work specifically on these processes in the context of sport (+ role Play and blog) to strengthen the ability to interact with others and to deal with the stigma that can be encountered on a daily basis.

NCT ID: NCT03774927 Completed - Schizophrenia Clinical Trials

High Frequency rTMS Treatment for Cognitive Impairments in Chronic Schizophrenia Patients

Start date: January 1, 2017
Phase: N/A
Study type: Interventional

A randomized, double-blind sham-controlled trial of high frequency rTMS treatment for cognitive impairments in 120 chronic schizophrenia patients

NCT ID: NCT03772951 Not yet recruiting - Schizophrenia Clinical Trials

The Efficacy of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

The study group received antipsychotic drugs combined with Computerized Cognitive Remediation Therapy (CCRT) for 4 times/week for 45 minutes each time. The control group only received antipsychotic drugs. For a total of 12 weeks. Brain Derived Neurotrophic Factor (BDNF) and Tropomyosin-related kinase B (Trk B) genes in peripheral blood were detected in both groups before and after treatment. Clinical symptoms and executive function assessment were performed in both groups before and after treatment. The relevance of genes and their effects on downstream protein expression levels led to a molecular genetic mechanism for the efficacy of Computerized Cognitive Remediation Therapy (CCRT) .

NCT ID: NCT03758495 Recruiting - Schizophrenia Clinical Trials

Ford Rumination and Mindfulness Merit

Start date: November 2018
Phase:
Study type: Observational

The investigators will acquire simultaneous EEG and fMRI data from veterans with depression and schizophrenia and mentally healthy veterans to assess early sensory responses, context updating, and responses to emotional images. Understanding how rumination affects engagement with the environment is the first step towards assessing its far-reaching cognitive and emotional costs, which cut across traditional diagnostic boundaries. Understanding how mindfulness restores information processing will increase our understanding of how, and for whom, it works.

NCT ID: NCT03757988 Recruiting - Schizophrenia Clinical Trials

Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life

PACE-life
Start date: December 6, 2018
Phase: N/A
Study type: Interventional

Purpose: To develop and test the feasibility of an exercise intervention that combines group walking, activity tracking, and heart rate monitoring, and determine the effectiveness of this intervention on the physical and mental health for individuals with schizophrenia spectrum disorders. Participants: 14 individuals with schizophrenia spectrum disorders. Procedures (methods): During the baseline assessment, subjects will be provided with a Fitbit wristband and instructed how to use it. During the first group session, subjects will be taught how to use their heart rate (on the Fitbit) to determine how fast subjects should walk (to achieve the appropriate exercise dosage). Information on proper care, usage, and how to determine the appropriate heart from the watch, which will be used to guide the intensity of the walk will be provided to subjects and reviewed at each group session. For all clinic based group sessions, subjects will arrive at the STEP clinic to meet the entire group and leaders and be reminded of the heart rate (HR) that corresponds with the intensity of that group session. Next, the group will go outside and walk for 30 minutes. At the completion of 30 minutes, everyone will go back into the clinic for water and review of the walk. After the second group session of each week, subjects will receive weekly progress reports of their steps and minutes spent walking the prior week (obtained from Fitbit devices). During this session, subjects will also set individual goals for the upcoming week for both their "intensity walks" and total steps per day.

NCT ID: NCT03756610 Recruiting - Schizophrenia Clinical Trials

Transcranial Alternating Current Stimulation (tACS) for Cognitive Impairments in Patients With Schizophrenia

Start date: November 2018
Phase: N/A
Study type: Interventional

This trial attempts to investigate whether 10 sessions of tACS improves cognitive function, especially which domains of cognitive function are most improved and to investigate whether 10 sessions of tACS affecting brain activation during a working memory task and changes patterns of brain connectivity networks.Subjects will be divided into 2 groups 2:1, active and sham tACS. 50 subjects will be in the active group, and 25 subjects in the sham group (specific numbers to be decided on later).

NCT ID: NCT03751865 Not yet recruiting - Clinical trials for Prodromal Schizophrenia

Early Detection and Intervention for Women At-risk of Psychosis

Start date: November 15, 2018
Phase: N/A
Study type: Interventional

This study aims to examine the effectiveness of the cognitive behavioral therapy in preventing the conversion of psychosis in a sample of individuals at-risk for psychosis.

NCT ID: NCT03751488 Not yet recruiting - Schizophrenia Clinical Trials

A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

Start date: December 1, 2018
Phase: Phase 1
Study type: Interventional

This study will look at the Characteristics of LY03010 Versus INVEGA SUSTENNA® in the blood of Schizophrenia Patients

NCT ID: NCT03751280 Not yet recruiting - Schizophrenia Clinical Trials

Study of Efficacy of PEAR-004 in Schizophrenia

Start date: December 7, 2018
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine in patients currently being administered antipsychotic pharmacotherapy whether PEAR-004 can further reduce symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS). The overall rationale for the study is to assess the first prescription digital therapeutic (PDT) in schizophrenia using a form of proven psychosocial intervention, cognitive behavioral therapy (CBT), to supplement standard of care with antipsychotic medications.

NCT ID: NCT03745820 Recruiting - Schizophrenia Clinical Trials

A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)

Start date: November 15, 2018
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to evaluate the efficacy of BIIB104 in participants with CIAS, using the Working Memory Domain of the MATRICS Consensus Cognitive Battery (MCCB). The secondary objectives of this study are to evaluate the safety and tolerability of BIIB104 in participants with CIAS, and to evaluate the efficacy of BIIB104 in participants with CIAS on measures of cognition, functioning, and psychiatric symptomology.